We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Apoptosis in patients with primary antiphospholipid antibody syndrome.
- Authors
Tang, Kuo‐Tung; Hsieh, Tsu‐Yi; Chao, Ya‐Hsuan; Li, Ju‐Pi; Lan, Joung‐Liang; Lin, Chi‐Chien; Chen, Der‐Yuan
- Abstract
Aim: Dysregulated apoptosis has been implicated in autoimmune diseases. In the present study, we investigated the apoptosis‐related cytokines and apoptosis in patients with primary antiphospholipid syndrome (pAPS). Method: We prospectively recruited 12 pAPS patients, 17 antiphospholipid antibody (APA)‐positive systemic lupus erythematosus (SLE) patients without APS manifestations (APA+SLE), 13 SLE patients with secondary APS (APS+SLE) and 10 healthy controls (HCs). Plasma levels of soluble apoptosis‐inducing ligands and cytokines, and the expression levels of apoptosis‐inducing ligands in peripheral blood mononuclear cells, were determined. In addition, blood lymphocytes/monocytes apoptosis were determined in six pAPS patients and six HCs, using flow cytometric analysis of caspase 3, 8 and 9 activities. Results: There was a trend toward higher plasma levels of soluble tumor necrosis factor (TNF)‐related apoptosis‐inducing ligand (sTRAIL), interleukin‐10 (IL‐10) and TNF‐α in pAPS patients when compared with HCs. We also observed higher plasma levels of IL‐10 and TNF α in APA+SLE and APS+SLE patients when compared with HCs. However, there was no significant difference in blood lymphocytes/monocytes apoptosis between pAPS patients and HCs. Conclusion: There was a trend toward elevated plasma levels of sTRAIL, IL‐10 and TNF‐α, but no evidence for dysregulated apoptosis in pAPS patients.
- Subjects
ANTIPHOSPHOLIPID syndrome; PHOSPHOLIPID antibodies; TUMOR necrosis factors; SYSTEMIC lupus erythematosus; APOPTOSIS; BLOOD cells
- Publication
International Journal of Rheumatic Diseases, 2019, Vol 22, Issue 4, p677
- ISSN
1756-1841
- Publication type
Article
- DOI
10.1111/1756-185X.13468